Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
木曜日, 9 03

Adicet Bio Inc

ACETNASDAQ
Trade with Public
Trade with Public
$9.26
N/A
近くで: Sep 1, 5:00 PM EST
$9.27
0.010.11%
プレマーケット: 4:17 AM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Adicet Bio Financials

Adicet Bio (ACET) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Adicet Bio Q2 EPS $(1.99) Beats $(2.03) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.03) by 1.97 percent. This is a 63.42 percent increase over losses of $(5.44) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q1 EPS $(1.88) Beats $(3.21) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(3.21) by 41.43 percent. This is a 62.1 percent increase over losses of $(4.96) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q4 EPS $(2.94) Beats $(3.10) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.10) by 5.04 percent. This is a 42.58 percent increase over losses of $(5.12) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Estimate

Benzinga Newsdesk

PRO
Adicet Bio Q2 EPS $(0.34) Misses $(0.30) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 12.58 percent. This is a 3.03 percent decrease over losses of $(0.33) per share from the
Benzinga Newsdesk

PRO
Adicet Bio Q1 EPS $(0.31) Beats $(0.34) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) by 8.82 percent. This is a 11.43 percent increase over losses of $(0.35) per share from the
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved